The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft
Open accessAbstract
SUMMARY Clinical application of umbilical cord blood (UCB) as a source of hematopoietic stem cells for transplantation is limited by low CD34+ cell dose, increased risk of graft failure and slow hematopoietic recovery. While the cell dose limitation is partially mitigated by using two UCB units, larger dosed single units would be preferable. We have evaluated the feasibility and safety of StemRegenin-1 (SR-1), an aryl hydrocarbon receptor antagonist that expands CD34+ cells, by placing one of the two units in expansion culture. SR-1 produced a 330-fold increase in CD34+ cells and led to engraftment in 17/17 patients at a median of 15 days for neutrophils and 49 days for platelets, significantly faster than in patients treated with unmanipulated UCB. Taken together, the marked expansion, absence of graft failure and enhanced hematopoietic recovery support testing of SR-1 expansion as a stand-alone graft and suggest it may ameliorate a limitation of UCB transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA processing is not required for ATM-mediated telomere damage response after TRF2 deletion
Celli, G. B., & de Lange, T. (2005) · Nature Cell Biology · doi:10.1038/ncb1275 · Cited by 623
Cited by
From haematopoietic stem cells to complex differentiation landscapes
Laurenti, E., & Göttgens, B. (2018) · Nature · doi:10.1038/nature25022 · Cited by 844
Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
Cheong, J. E., & Sun, L. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.11.007 · Cited by 487
Haematopoietic stem cell self-renewal in vivo and ex vivo
Wilkinson, A. C., Igarashi, K. J., & Nakauchi, H. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0241-0 · Cited by 226
Chemical reprogramming for cell fate manipulation: Methods, applications, and perspectives
Wang, J., Sun, S., & Deng, H. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.08.001 · Cited by 91
Murine foetal liver supports limited detectable expansion of life‐long haematopoietic progenitors
Ganuza, M., Hall, T., Myers, J., Nevitt, C., Sánchez-Lanzas, R., Chabot, A., Ding, J., Kooienga, E., Caprio, C., Finkelstein, D., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00999-5 · Cited by 83
Metadata
- Authors
- Wagner, J. E., Brunstein, C. G., Boitano, A. E., DeFor, T. E., McKenna, D., Sumstad, D., Blazar, B. R., Tolar, J., Le, C., Jones, J., Cooke, M. P., & Bleul, C. C.
- Venue
- Cell Stem Cell
- Publisher
- Elsevier BV
- Published
- 2016-01
- Volume
- 18
- Issue
- 1
- Pages
- 144-155
- ISSN
- 1875-9777 (ISSN-L)
- 1934-5909
- OpenAlex
- W2189304488
- Cited by
- 335
- References
- 1
- FWCI
- 23.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft. https://app.cochat.ai/papers/10.1016/j.stem.2015.10.004
- The paper
- Wagner, J. E., Brunstein, C. G., Boitano, A. E., DeFor, T. E., McKenna, D., Sumstad, D., Blazar, B. R., Tolar, J., Le, C., Jones, J., Cooke, M. P., & Bleul, C. C. (2016). Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft. Cell Stem Cell. https://doi.org/10.1016/j.stem.2015.10.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.